Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Kalaris Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 30 | 32 | +2 |
| Shares | 13.4M | 13.2M | −139.4K (−1.0%) |
| Value | $35.7M | $76.4M | +$40.8M (+114.2%) |
New holders (8)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 241,102 | $1.39M | 0.01% |
| Belpointe Asset Management LLC | 40,000 | $231.2K | 0.01% |
| Fortis Capital Advisors, LLC | 40,000 | $231.2K | 0.04% |
| Bridgeway Capital Management, LLC | 22,500 | $130.1K | 0.00% |
| Goldman Sachs Group Inc | 22,465 | $129.8K | 0.00% |
| Johnson Financial Group, Inc. | 10,000 | $57.8K | 0.00% |
| Strengthening Families & Communities, LLC | 268 | $1.55K | 0.00% |
| Citigroup Inc | 1 | $6 | 0.00% |
Sold out (6)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Octagon Capital Advisors LP | 360,000 | $961.2K |
| Gilead Sciences, Inc. | 317,789 | $848.5K |
| XTX Topco Ltd | 24,234 | $64.7K |
| Two Sigma Advisers, LP | 20,281 | $54.1K |
| Raymond James Financial Inc | 2,629 | $7.02K |
| Tower Research Capital LLC (TRC) | 2,153 | $5.75K |